(Q54311380)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22564111%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

title

Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22564111%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22564111%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Per Soelberg Sørensen

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22564111%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

author name string

P E H Jensen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22564111%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

H B Søndergaard

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22564111%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

publication date

5 May 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22564111%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Neurology

31 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22564111%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22564111%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22564111%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

page(s)

1311-1317

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22564111%20AND%20SRC:MED&resulttype=core&format=json

Interferons, interferon-like cytokines, and their receptors

31 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03721.X

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03721.X

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03721.X

The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03721.X

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03721.X

On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03721.X

HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03721.X

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03721.X

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03721.X

Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03721.X

Critical review: assessment of interferon-β immunogenicity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03721.X

Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03721.X

Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03721.X

Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03721.X

Kinetic maturation of an immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03721.X

Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03721.X

Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03721.X

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03721.X

Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03721.X

A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03721.X

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2012.03721.X

10.1111/J.1468-1331.2012.03721.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22564111%20AND%20SRC:MED&resulttype=core&format=json

release_6g7q5pssivd2fj4bjstpf2k5lm

31 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6g7q5pssivd2fj4bjstpf2k5lm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22564111%20AND%20SRC:MED&resulttype=core&format=json